Structure-activity relationships of new 2-acylamino-3-thiophenecarboxylic acid dimers as plasminogen activator inhibitor-1 inhibitors

Chemical and Pharmaceutical Bulletin

Volumn 58, Issue 5, 2010, Pages 615-619

  Yamaoka, Nagahisa ^a   Kawano, Yasuhiko ^a   Izuhara, Yuko ^b   Miyata, Toshio ^c   Meguro, Kanji ^a  

^a Technology Department / Yonezawa Hamari Chemicals Ltd 2 4300 18   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aminothiophenecarboxylic acid derivative; Inhibitor; Plasminogen activator inhibitor 1; Structure activity relationship; Tissue type plasminogen activator

Indexed keywords

2 [[(2 [[3 (TERT BUTOXYCARBONYL) 5 METHYL 4 PHENYLTHIOPHEN 2 YL]AMINO] 2 OXOETHOXY]ACETYL]AMINO] 5 METHYL 4 PHENYLTHIOPHENE 3 CARBOXYLIC ACID; 2,2' [(1,4 DIOXOBUTANE 1,4 DIYL)DIIMINO]BIS[4 (2 METHYLPROPYL)THIOPHENE 3 CARBOXYLIC ACID]; 2,2' [(1,5 DIOXOPENTANE 1,5 DIYL)DIIMINO]BIS[4 (2 METHYLPROPYL)THIOPHENE 3 CARBOXYLIC ACID]; 2,2' [(1,6 DIOXOHEXANE 1,6 DIYL)DIIMINO]BIS(5 METHYLTHIOPHENE 3 CARBOXYLIC ACID); 2,2' [(1,6 DIOXOHEXANE 1,6 DIYL)DIIMINO]BIS(5 PHENYLTHIOPHENE 3 CARBOXYLIC ACID); 2,2' [(1,6 DIOXOHEXANE 1,6 DIYL)DIIMINO]BIS[4 (2 METHYLPROPYL)THIOPHENE-3-CARBOXYLIC ACID]; 2,2' [(1,6 DIOXOHEXANE 1,6 DIYL)DIIMINO]BIS[4 (PROPAN 2 YL)THIOPHENE 3 CARBOXYLIC ACID]; 2,2' [(1,7 DIOXOHEPTANE 1,7 DIYL)DIIMINO]BIS(4 PHENYLTHIOPHENE 3 CARBOXYLIC ACID); 2,2' [(3,3 DIMETHYL 1,5 DIOXOPENTANE 1,5 DIYL)DIIMINO]BIS[4 (2 METHYLPROPYL)THIOPHENE 3 CARBOXYLIC ACID]; 2,2' [OXYBIS[(1 OXOETHANE 2,1 DIYL)IMINO]]BIS(4 PHENYLTHIOPHENE 3 CARBOXYLIC ACID); 2,2' [OXYBIS[(1 OXOETHANE 2,1 DIYL)IMINO]]BIS(5 METHYL 4 PHENYLTHIOPHENE 3 CARBOXYLIC ACID); 2,2' [OXYBIS[(1 OXOETHANE 2,1 DIYL)IMINO]]BIS(5 PHENYLTHIOPHENE 3 CARBOXYLIC ACID); CARBOXYL GROUP; CARBOXYLIC ACID; DIAPLASININ; DIMER; PAI 039; PAI 749; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN INHIBITOR; THIOPHENE DERIVATIVE; TIPLAXININ; TM 5001; TM 5007; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROPHOBICITY; MOLECULAR WEIGHT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ACYLATION; AMINES; CARBOXYLIC ACIDS; DIMERIZATION; HUMANS; MOLECULAR STRUCTURE; PLASMINOGEN ACTIVATOR INHIBITOR 1; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 77951730692     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.58.615     Document Type: Article

References (13)

1. Dellas C., Loskutoff D. J., Thromb. Haemost., 93, 631-640 (2005).
2. Crandall D. L., Quinet E. M., El Ayachi S., Hreha A. L., Leik C. E., Savio D. A., Juhan-Vague I., Alessi M. C., Arterioscler. Thromb. Vasc. Biol., 26, 2209-2215 (2006).
3. Ma L. J., Mao S. L., Taylor K. L., Kanjanabuch T., Guan Y., Zhang Y., Brown N. J., Swift L. L., McGuinness O. P., Wasserman D. H., Vaughan D. E., Fogo A. B., Diabetes, 53, 336-346 (2004).
4. Ha H., Oh E. Y., Lee H. B., Nat. Rev. Nephrol., 5, 203-211 (2009).
5. Oda T., Jung Y. O., Kim H. S., Cai X., López-Guisa J. M., Ikeda Y., Eddy A. A., Kidney Int., 60, 587-596 (2001).
6. Elokdah H., Abou-Gharbia M., Hennan J. K., McFarlane G., Mugford C. P., Krishnamurthy G., Crandall D. L., J. Med. Chem., 47, 3491-3494 (2004).
7. Gardell S. J., Krueger J. A., Antrilli T. A., Elokdah H., Mayer S., Orcutt S. J., Crandall D. L., Vlasuk G. P., Mol. Pharmacol., 72, 897-906 (2007).
8. Izuhara Y., Takahashi S., Nangaku M., Takizawa S., Ishida H., Kurokawa K., van Ypersele de Strihou C., Hirayama N., Miyata T., Arterioscler. Thromb. Vasc. Biol., 28, 672-677 (2008).
9. Sabnis R. W., Rangnekar D. W., Sonawane N. D., J. Heterocycl. Chem., 36, 333-345 (1999).
10. Gütschow M., Neumann U., J. Med. Chem., 41, 1729-1740 (1998).
11. Gütschow M., Schröter H., Kuhnle G., Eger K., Monatsh. Chem., 127, 297-303 (1996).
12. Hodson H. F., Dunk C. R., Palmer R. M. J., Mitchell D. R., Birault V., Hunt R. G., PCT Int. Appl. WO2003020282 (2003).
13. Thede K., Wunberg T., Lowinger T., Koletzki D., Urban A., Baumeister J., Henninger K., PCT Int. Appl. WO 2005063734 (2005).